$413 Million is the total value of Abingworth LLP's 20 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $99,174,000 | -6.2% | 4,168,718 | 0.0% | 24.03% | +0.1% | |
| VERA | Vera | $78,535,000 | +52.9% | 2,960,231 | 0.0% | 19.03% | +63.3% | |
| Jasper | $44,128,000 | -24.0% | 5,628,558 | 0.0% | 10.69% | -18.8% | ||
| eFFECTOR | $39,927,000 | -40.4% | 4,822,114 | 0.0% | 9.68% | -36.4% | ||
| ACET | Buy | Adicet | $36,892,000 | +191.7% | 2,115,385 | +31.0% | 8.94% | +211.5% |
| PHAT | Phathom | $23,606,000 | -38.7% | 1,203,135 | 0.0% | 5.72% | -34.5% | |
| SRRA | Sierra Oncology | $19,050,000 | +0.1% | 876,656 | 0.0% | 4.62% | +6.9% | |
| RPHM | Reneo | $17,732,000 | +15.8% | 2,073,957 | 0.0% | 4.30% | +23.7% | |
| VRNA | Veronasponds adr | $16,318,000 | +21.8% | 2,457,499 | 0.0% | 3.95% | +30.1% | |
| SIEN | Sientra | $8,600,000 | -36.1% | 2,349,827 | 0.0% | 2.08% | -31.8% | |
| Spruce Bio | $7,959,000 | -25.7% | 1,792,518 | 0.0% | 1.93% | -20.7% | ||
| NCNA | Nucanaadr | $7,933,000 | -7.4% | 3,333,333 | 0.0% | 1.92% | -1.1% | |
| PRTK | Paratek | $4,654,000 | -8.0% | 1,041,131 | 0.0% | 1.13% | -1.7% | |
| SLNO | Soleno | $4,224,000 | -55.5% | 10,302,602 | 0.0% | 1.02% | -52.5% | |
| XCUR | Exicure | $1,398,000 | -83.0% | 6,977,000 | 0.0% | 0.34% | -81.9% | |
| AGLE | Aeglea | $1,142,000 | -40.3% | 240,500 | 0.0% | 0.28% | -36.2% | |
| MTEM | Molecular Templates | $780,000 | -41.8% | 200,000 | 0.0% | 0.19% | -37.8% | |
| CBAY | Cymabay | $442,000 | -7.5% | 131,036 | 0.0% | 0.11% | -0.9% | |
| OBSV | Obseva | $174,000 | -36.5% | 87,999 | 0.0% | 0.04% | -32.3% | |
| HSGX | Ocugen | $32,000 | -37.3% | 7,111 | 0.0% | 0.01% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.